Daniel Gau,
Head of Business Development,
Unicyte AG
Dr. Daniel Gau, is Unicyte’s Head of Business Development, an independent affiliate of Fresenius Medical Care KGaA. He is also Senior Director of External Venture Management at Fresenius Medical Care, which he joined in 2016.
Dr. Gau joined Unicyte from Merck KGaA, a leading company in healthcare, and life sciences where he was Associate Director In-house Consulting, Head of Business Development Functional Materials as then Head of Global Marketing Functional Materials.
Prior to joining Merck, Dr. Gau served as General Manager and Vice President of TF Instruments, a start-up located in Heidelberg and Princeton, New Jersey and as Analyst with TechnoStart, a German early stage venture capital organization. Dr. Gau Ph.D. holds in Molecular and Neurobiology from the University of Heidelberg and his research contributed to publications in Neuron, Nature Genetics and Genes & Development.
Human Liver Stem Cell-derived Nano-EVs – A Broad Platform Technology for Cancer and Regeneration
Thursday, 28 March 2019 at 15:30
Add to Calendar ▼2019-03-28 15:30:002019-03-28 16:30:00Europe/LondonHuman Liver Stem Cell-derived Nano-EVs – A Broad Platform Technology for Cancer and RegenerationExtracellular Vesicle-based Dx and Rx Summit in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Extracellular vesicles and exosomes (EVs), and in particular when derived from stem cells are emerging as a new therapeutic modality in regenerative medicine. Stem cell derived EVs are of high abundance, are not self-replicating, are not immunogenic, own a tissue specific targeting capability and thus address hurdles of stem cells for translation into indications with large patient impact. With more than 10 years research in the field, Unicyte has developed a strong therapeutic pipeline in fibrotic disorders and oncology, using it’s proprietary Human Liver Stem Cell and derived nano-EVs (HLSC-nEVs). With their natural targeting capability to liver tissue and to tumor cells, HLSC-nEVs have been investigated in Hepatocellular carcinoma (HCC) the most common cause of death in people with cirrhosis. In pre-clinical studies, HLSC-nEVs decrease the growth and survival rates of tumor liver cells, while at the same time protecting normal hepatocytes. In addition, HLSC-nEVs have demonstrated strong liver regeneration capabilities in various models of acute and chronic liver injury, ex-vivo scaffold re-cellularization and more recently on normothermic transplantation models. These results suggest that HLSC-nEV address the underlying liver disease and inhibit tumor growth in hepato-cellular carcinoma via a multi-factorial mechanism of action. Unicyte is currently preparing clinical transition of its HLSC-nEVs programs in various indications.
Add to Calendar ▼2019-03-28 00:00:002019-03-28 00:00:00Europe/LondonExtracellular Vesicle-based Dx and Rx SummitExtracellular Vesicle-based Dx and Rx Summit in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2019-03-28 15:30:002019-03-28 16:30:00Europe/LondonHuman Liver Stem Cell-derived Nano-EVs – A Broad Platform Technology for Cancer and RegenerationExtracellular Vesicle-based Dx and Rx Summit in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
